RxDoctor Payments Data

Tanya Malhotra, OD

Optometrist · Annapolis, MDNPI 1134796345

Payments from drug & device makers

$645in general payments, 2019–2025

Across 18 payments — averaging $35.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$172
  • Johnson & Johnson Vision Care, Inc.$126
  • Sight Sciences, Inc.$79
  • Bausch & Lomb Americas Inc.$72
  • Sun Pharmaceutical Industries Inc.$57
  • Dompe US, Inc.$41
  • plus $99 from 4 others

What the payments were for

  • Food & beverage$645100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$645 in reported general payments places this provider in the 45th percentile of 790 optometrist providers in Maryland.

See all optometrist providers in Maryland

Medicare billing

Part B allowed, 2024
$106,219
Medicare patients
506
Services billed
1,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$37,345
RocklatanNetarsudil Mesylat/Latanoprost38$13,564
LumiganBimatoprost21$12,865
Cyclosporine18$5,963
Travoprost36$5,712
Latanoprost342$5,196
CombiganBrimonidine Tartrate/Timolol14$3,190
Brimonidine Tartrate95$3,098
Brinzolamide13$3,050
Dorzolamide Hcl82$1,744
Prednisolone Acetate27$1,637
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat87$1,431
Fluorometholone19$1,398
Timolol Maleate67$743
ErythromycinErythromycin Base59$598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$25$53,40070 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 790 optometrist providers in Maryland.

Other optometrist in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →